BsAbs targeting both CTLA-4 and another molecule, such as PD-1 (17, 51) or PD-L1 (52), enhance the immune response against cancer by blocking two separate immune checkpoints that can inhibit anti-tumor immunity. This evidence concerns the gene CTLA4 and neoplasm.